Category Archives: Uncategorized

Pravin U. Dugel, MD: Clinical Effectiveness of Switching Between Ranibizumab and Aflibercept in Treatment of Neovascular AMD: US Real-World Outcomes

Purpose: The purpose of this article is to examine visual acuity (VA) outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes switching between ranibizumab and aflibercept in routine clinical practice. Methods: Electronic medical records were used to identify nAMD eyes receiving ranibizumab or aflibercept with 12 months’ follow-up since switching antivascular endothelial growth… Read More »


Dr. Pravin U. Dugel – HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration

Pravin U. Dugel, Adrian Koh, Yuichiro Ogura, Glenn Jaffe, Ursula Schmidt-Erfurth, David Brown, Andre V. Gomes, James Warburton, Andreas Weichselberger, Frank G. Holz Abstract ObjectiveTwo similarly designed, phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (AMD). DesignDouble-masked, multicenter, active-controlled, randomized trials. Patients(N = 1817) with untreated,… Read More »


Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. VBS 2019

Pravin Dugel, MD, R. Ross Lakhanpal, MD   Channels: Retina | Posted 4/5/2019 Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. In Dr. Dugel’s view, the informatics platforms used in other fields could translate to retina and, when they arrive, will change the preparation and… Read More »


Positive preliminary data in US retinal trial: Significant improvement in vision in first cohort of Phase II subjects in US trial of hRPC cell therapy in retinitis pigmentosa

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the ongoing Phase I/II clinical trial of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP). The Company is pleased to report that all three of the first… Read More »


Dr. Pravin U. Dugel Invited to Speak at First Gene Therapy for Chronic Retinal Diseases Summit in New York

ROCKVILLE, Md., Feb. 14, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will host an analyst and investor event focused on its ophthalmology program, including its lead product candidate RGX-314, on Thursday, February 21,… Read More »


Graybug Vision Presents Top Line Results Of Phase 1/2a ADAGIO Study At Hawaiian Eye & Retina 2019

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019 ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment… Read More »


Pravin U. Dugel, MD: Association Between Early Anatomic Responses to Anti-Vascular Endothelial Growth Factor Therapy and Long-term Outcome in Diabetic Macular Edema

An Independent Analysis of Protocol i Study Data Dugel, Pravin U., MD*,†; Campbell, Joanna H., PhD‡; Kiss, Szilárd, MD§; Loewenstein, Anat, MD¶; Shih, Vanessa, PharmD‡; Xu, Xiaoshu, MS‡; Holekamp, Nancy M., MD**; Augustin, Albert J., MD, PhD††; Ho, Allen C., MD‡‡; Gonzalez, Victor H., MD§§; Whitcup, Scott M., MD¶¶ RETINA: January 2019 – Volume 39… Read More »


Dr. Pravin U. Dugel: Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration

Neovascular age-related macular degeneration (nAMD) is the leading cause of severe vision loss and irreversible blindness in people aged over 65 years in North America, Europe, Australia, and Asia.1 Anti-vascular endothelial growth factor (anti-VEGF) therapies have led to great improvements in outcomes for patients with nAMD.2 However, currently available anti-VEGF treatments require frequent clinic visits to monitor… Read More »


Dr. Pravin U. Dugel – AAO eXtract Project: HAWK AND HARRIER

American Academy of Ophthalmology (AAO) Annual Meeting: HAWK AND HARRIER Trials Reaffirm Direction for a Novel Anti-VEGF Dr. Dugel has authored more than 200 papers, 35 book chapters and has been invited to lecture at prestigious meetings, Visiting Professorships and Universities worldwide, including Japan, India, China, Malaysia, Egypt, United Kingdom, France, Germany, Austria, Italy, Poland,… Read More »


Dr. Pravin U. Dugel: Anatomy in HAWK and HARRIER

Retina Subspecialty Day Coverage – American Academy of Ophthalmology 2018 Series: 2018 Pravin U. Dugel, MD   Channels: Retina Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the… Read More »